This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
https://www.barrons.com/articles/provention-bio-stock-sanofi-acquisition-7f5a2c9d
- Order Reprints
- Print Article
Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion.
Provention Bio (ticker: PRVB), which focuses on autoimmune diseases, jumped 258% to $24 on Monday. The stock closed Friday at $6.70. American depositary receipts of Sanofi fell 0.2%.
